ylliX - Online Advertising Network
Press Release

Phase 3 trial of Libtayo® (cemiplimab) combined with chemotherapy stopped early due to significant improvement in overall survival in patients with first-line advanced non-small cell lung cancer

Phase 3 trial of Libtayo® (cemiplimab) combined with chemotherapy stopped early due to significant improvement in overall survival in patients with first-line advanced non-small cell lung cancer

<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>

Phase 3 t rial of Libtayo ® ( cemiplimab ) c ombined with c hemotherapy s topped e arly d ue to s ignificant i mprovement in o verall s urvival in p atients with f irst-line a dvanced n on-small c ell l ung c ancer

...read full article on GlobeNewsWire

ylliX - Online Advertising Network